Amniotics™
Amniotics AB is a biopharmaceutical company dedicated to providing unique stem cell therapeutics to patients in need.
Our Technology
Amniotics™ has developed a unique pipeline of cell therapeutics combining the desirable properties of neonatal source and tissue specificity. Our product is tailored to the organ of choice (such as e.g. lung, kidney, or CNS/brain). Our technology combines unique properties of neonatal cells with tissue-relevance, making it possible to treat corresponding tissues.
A Novel Source
Our cells originate from full term amniotic fluid, collected at planned cesarean and processed with our technology which ensures the properties are ideal for regenerative and immunomodulatory medicine. We have developed a proprietary method and a device for the extraction (according to GMP protocols) and use of the amniotic fluid material.
Harvesting nature’s powers
Mesenchymal stem cells (MSCs) have been shown to aid in healing damaged organs and tissues, and to modulate deleterious inflammatory processes in a wide spectrum of diseases that have a high unmet medical need. With our technology, we tap straight into the healing properties provided by tissue-relevant neonatal stem cells.
In the News
CEO Kåre Engkilde presented at the annual Cell & Gene Meeting, which was held virtually April 6-9 2021
The Cell & Gene Meeting is organized by the Alliance for Regenerative Medicine. This year featuring more than 90 company presentations by leading public and private companies, highlighting technical and clinical achievements…
Annual General Meeting 2021
The shareholders in Amniotics AB (publ), org. No. 559024-6558 (“Amniotics”), is hereby called to the Annual General Meeting on Thursday, April 15, 2021…
Amniotics approved as Tissue Establishment
On the 27th of October 2020, Amniotics was approved to carry out activities as a Tissue Establishment by the Swedish Medical Products Agency. The authorization refers to the handling of human tissues and cells intended for the manufacture of medicinal products...
COVID19 – The Corona virus pandemic calls us to action
Amniotics AB is uniquely positioned to, and we believe it is our duty to, explore a novel treatment modality for severe respiratory issues related to infections from the corona virus SARS-CoV-2. Our research and development program over the last decade geared towards treatment of severe respiratory diseases has created the knowledge and experience that may be applied to treating respiratory issues associated with COVID19. The severity of the most affected patients calls us to action. We are answering that call.